Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meletios A Dimopoulos

Showing results (601-610 of 652) with videos related to

Pageof 66
Sort By:
Blood|July 21, 2021
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIAMichele Cavo, Jesus San-Miguel, Saad Z Usmani, et al.
The Lancet. Oncology|December 17, 2015
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre studyMeletios A Dimopoulos, Philippe Moreau, Antonio Palumbo, et al.
Journal of Cellular and Molecular Medicine|February 10, 2024
Genetic justification of COVID-19 patient outcomes using DERGA, a novel data ensemble refinement greedy algorithmPanagiotis G Asteris, Amir H Gandomi, Danial J Armaghani, et al.
Lancet (London, England)|December 15, 2019
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trialMaria-Victoria Mateos, Michele Cavo, Joan Blade, et al.
Blood Cancer Journal|September 5, 2020
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 studyMeletios A Dimopoulos, Sagar Lonial, Darrell White, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2019
Progression Risk Stratification of Asymptomatic Waldenström MacroglobulinemiaMark Bustoros, Romanos Sklavenitis-Pistofidis, Prashant Kapoor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2015
Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statementMeletios A Dimopoulos, Jens Hillengass, Saad Usmani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2025
Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA StudyRakesh Popat, Meral Beksac, Meletios A Dimopoulos, et al.
JAMA Oncology|August 1, 2024
Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain AmyloidosisEli Muchtar, Brendan Wisniowski, Susan Geyer, et al.
Blood|May 27, 2016
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myelomaMeletios A Dimopoulos, Antonio Palumbo, Paolo Corradini, et al.
Pageof 66

Showing results (601-610 of 652) with videos related to

Sort By:
Pageof 66
Blood|July 21, 2021
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIAMichele Cavo, Jesus San-Miguel, Saad Z Usmani, et al.
The Lancet. Oncology|December 17, 2015
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre studyMeletios A Dimopoulos, Philippe Moreau, Antonio Palumbo, et al.
Journal of Cellular and Molecular Medicine|February 10, 2024
Genetic justification of COVID-19 patient outcomes using DERGA, a novel data ensemble refinement greedy algorithmPanagiotis G Asteris, Amir H Gandomi, Danial J Armaghani, et al.
Lancet (London, England)|December 15, 2019
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trialMaria-Victoria Mateos, Michele Cavo, Joan Blade, et al.
Blood Cancer Journal|September 5, 2020
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 studyMeletios A Dimopoulos, Sagar Lonial, Darrell White, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2019
Progression Risk Stratification of Asymptomatic Waldenström MacroglobulinemiaMark Bustoros, Romanos Sklavenitis-Pistofidis, Prashant Kapoor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2015
Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statementMeletios A Dimopoulos, Jens Hillengass, Saad Usmani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2025
Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA StudyRakesh Popat, Meral Beksac, Meletios A Dimopoulos, et al.
JAMA Oncology|August 1, 2024
Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain AmyloidosisEli Muchtar, Brendan Wisniowski, Susan Geyer, et al.
Blood|May 27, 2016
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myelomaMeletios A Dimopoulos, Antonio Palumbo, Paolo Corradini, et al.
Pageof 66